Sheng-Min Wang

Sheng-Min Wang

Auto-generated profile, based on publicly available information

Sheng-Min Wang

Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
CPChi-Un Pae
Chi-Un Pae
SWSheng-Min Wang
Sheng-Min Wang
CHChangsu Han
Changsu Han
APAshwin Paktar
Ashwin Paktar
PMPrakash S Masand
Prakash S Masand
SLSoo-Jung Lee
Soo-Jung Lee
Improving medication adherence is critical to improving outcomes in patients with schizophrenia. A long-acting injectable (depot) antipsychotic is one of the most effective methods for improving treatment adherence and decreasing rehospitalization rates in patients with schizophrenia. Until recently, only three second-generation antipsychotics were available in a long-acting injectable formulation (risperidone, paliperidone, and olanzapine). In this respect, the emergence of long-acting aripiprazole injection (ALAI), approved by the US Food and Drug Administration for the treatment of schizophrenia in 2013, is timely. ALAI is a lyophilized powder of aripiprazole, and the aripiprazole molecule is unmodified. The initial and target dosage of ALAI is 400 mg once monthly, but it could be reduced to 300 mg if adverse reactions occur with 400 mg. When first administering ALAI, it is recommended to continue treatment with oral aripiprazole (10–20 mg/day) or another oral antipsychotic for 2 weeks in order to maintain therapeutic antipsychotic concentrations. The primary clearance route for ALAI is hepatic, ie, cytochrome P450 (CYP)2D6 and CYP3A4, so dose adjustment is required in poor CYP2D6 metabolizers. The efficacy of ALAI was demonstrated in three studies. A randomized controlled trial that formed the basis for approval of ALAI in the treatment of schizophrenia showed that ALAI significantly delayed time to impending relapse when compared with placebo (P<0.0001, log-rank test). An open-label, mirror study demonstrated that total psychiatric hospitalization rates were significantly lower after switching from oral antipsychotics to ALAI. Another randomized controlled trial presented in poster form suggested that ALAI 400 mg was comparable with oral aripiprazole 10–30 mg in preventing relapse. ALAI was generally well tolerated during both short-term and long-term studies. Its tolerability profile, including extrapyramidal symptoms and clinically relevant metabolic parameters, was similar to placebo. However, insomnia, headache, anxiety, akathisia, weight gain, injection site pain, and tremor need clinical attention. These studies suggest that ALAI is a viable treatment option for patients with schizophrenia, but direct head-to-head comparisons between ALAI and other long-acting injectable antipsychotics are needed to elucidate its risk–benefit profile.

31 May 2020 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
MCMarco Calabrò
Marco Calabrò
LMLaura Mandelli
Laura Mandelli
CCConcetta Crisafulli
Concetta Crisafulli
MNMarco Di Nicola
Marco Di Nicola
RCRoberto Colombo
Roberto Colombo
ASAlessandro Serretti
Alessandro Serretti
Marco Calabrò, Laura Mandelli, Concetta Crisafulli, Marco Di Nicola, Roberto Colombo, Luigi Janiri, Soo-Jung Lee, Tae-Youn Jun, Sheng-Min Wang, Prakash S. Masand, Ashwin A. Patkar, Changsu Han, Chi-Un Pae, Alessandro Serretti. Clin Psychopharmacol Neurosci 2020;18:231-40. https://doi.org/10.9758/cpn.2020.18.2.231

28 February 2021 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
CCConcetta Crisafulli
Concetta Crisafulli
MCMarco Calabrò
Marco Calabrò
LMLaura Mandelli
Laura Mandelli
SWSheng-Min Wang
Sheng-Min Wang
SLSoo-Jung Lee
Soo-Jung Lee
ASAlessandro Serretti
Alessandro Serretti
Concetta Crisafulli*, Marco Calabrò*, Laura Mandelli, Sheng-Min Wang, Soo-Jung Lee, Changsu Han, Ashwin Patkar, Prakash Masand, Chi-Un Pae, Daniel Souery, Julien Mendlewicz, Alessandro Serretti. Clin Psychopharmacol Neurosci 2021;19:46-52. https://doi.org/10.9758/cpn.2021.19.1.46